Public and decision-maker stated preferences for pharmaceutical subsidy decisions in Iran: an application of the discrete choice experiment

Table 3 Logit model estimation for public and decision-makers

Attributes	Levels	Groups	Estimate	Std error	Lower 95%	Upper 95%	L-R Chi Square	DF	Prob > ChiSq
Severity	2–1	Public	− 0.145	0.027	− 0.185	− 0.091	37.829	1	< .0001*
Severity	2–1	Decision-makers	− 0.412	0.148	− 0.588	0.077	12.867	1	< .0003*
Health gain	2–1	Public	− 0.783	0.029	− 0.839	− 0.721	1065.588	2	< .0001*
	2–1	Decision-makers	− 1.707	0.194	− 1.972	− 1.083	222.960	2	< .0001*
	3–2	Public	0.821	0.044	0.737	0.896
	3–2	Decision-makers	0.863	0.141	0.661	1.089
Prevalence	2–1	Public	− 0.345	0.024	− 0.395	− 0.297	217.295	1	< .0001*
Prevalence	2–1	Decision-makers	− 0.360	0.104	− 0.633	− 0.086	16.735	1	< .0001*
Cost	2–1	Public	− 0.726	0.048	− 0.818	− 0.617	455.225	3	< .0001*
	2–1	Decision-makers	− 0.197	0.156	− 0.655	0.209	40,354	3	< .0001*
	3–2	Public	0.544	0.055	0.440	0.620
	3–2	Decision-makers	− 0.565	0.187	− 0.945	0.400
	4–3	Public	0.485	0.037	0.409	0.555
	4–3	Decision-makers	0.771	0.190	0.468	1.083

ISSN: 2052-3211